SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
5 references·1 citing·30 second hop
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States (2017)Cost-Effectiveness of Pembrolizumab Versu…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Health Care Costs for Patients With Cancer at the End of Life (2012)Health Care Costs for Patient…A Prescription for Improving Drug Formulary Decision Making (2012)A Prescription for Improving …Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path (2011)Economic evaluation to inform…US Valuation of the EQ-5D Health States (2005)US Valuation of the EQ-5D Hea…Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation (2017)Modelling the Survival Outcom…Cost of Care for Elderly Cancer Patients in the United States (2008)Bending the Cost Curve in Cancer Care (2011)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States (2015)Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States (2017)Financial toxicity in cancer care: origins, impact, and solutions (2021)Specification Tests in Econometrics (1978)EuroQol - a new facility for the measurement of health-related quality of life (1990)Econometric Analysis of Cross Section and Panel Data (2001)Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States (2006)Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer (2007)Dutch Tariff for the Five-Level Version of EQ-5D (2016)25 years of the WHO essential medicines lists: progress and challenges (2003)Setting priorities for mental health care in Nepal: a formative study (2013)Body size perceptions and preferences favor overweight in adult Saharawi refugees (2018)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)The Structure of Scientific Revolutions (1963)The Structure of Scientific Revolutions (1996)Methods for the Economic Evaluation of Health Care Programmes (2005)Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023 (2024)The Value of Social Work to Health, Health Systems, and Interprofessional Teams: A Scoping Review (2024)Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Accounting for Cured Patients in Cost-Effectiveness Analysis (2016)Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods (2016)Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes (2019)
this work references cited by second hop

References

  • 2005US Valuation of the EQ-5D Health States1,274 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2012Health Care Costs for Patients With Cancer at the End of Life255 cited
  • 2012A Prescription for Improving Drug Formulary Decision Making86 cited
  • 2011Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path80 cited

Cited by

  • 2017Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation65 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work